What analyst predict for Brainstorm Cell Therapeutics NASDAQ:BCLI ?
Brainstorm Cell Therapeutics NASDAQ:BCLI headquartered in New York City, New York, United States is reporting their earnings on 05/14/2018 before the bell. Street forecast for the quarter ending March 2018 is $-0.14.
According to stock market daily analyst this is Lower then same time previous year. Brainstorm Cell Therapeutics reported EPS for the same quarter last year was $-0.1.
Overview of Brainstorm Cell Therapeutics NASDAQ:BCLI
BrainStorm Cell Therapeutics Inc. is a biotechnology company developing autologous adult stem cell therapies for neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS) and Parkinson’s disease (PD)
|% Change from 52 Week Low|
|% Change from 52 Week High|